SHARE THIS ARTICLE:

Hygromycin A: Antibiotic to Prevent Chronic Lyme

Kim Lewis, PhD
Professor of Biology Northeastern University Boston, MA

Northeastern Global News (Cynthia McCormick Hibbert) 05.26.23,  published an article on the research conducted by Kim Lewis, PhD., professor of biology and director of Northeastern’s Antimicrobial Discovery Center. According to Northeastern University,  Lewis has developed a treatment for Lyme disease that could prevent chronic Lyme from developing.

Hygromycin A is the antibiotic being investigated in preventing chronic Lyme, and the game changing advantage is that this antibiotic targets and selectively kills Lyme disease-causing bacteria without damaging other beneficial bacteria in a person’s gut microbiome. This news is groundbreaking as nearly 500,00 new cases of acute Lyme are being treated annually in the US. 

Northeastern states that human trials for this antibiotic treatment may begin as early as next year.

LDA Note:  Kim Lewis spoke on Hygromycin A during his talk on “Developing therapies for Lyme disease” at The Lyme Disease Association/Columbia University Vagelos College of Physicians & Surgeons Virtual Conference in 2021.  See video below.


For more information:

Read the article on Northeastern’s website

Read more Kim Lewis’s Research on Hygromycin A from 2021 LDA/Columbia Conference here